报价延迟最少15分钟:2026/07/07 02:17 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.1 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.77/-1.29
|
|
企业价值
127.27M
|
| 资产负债 |
|
每股账面净值
-3.42
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
642.00K
|
|
每股收益
0.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
